Highly sensitive immunoassay for determination of biomarkers for neurodegenerative diseases
Award amount
$1,823,681Program and phase
SBIR · Phase IIAward year
2023Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ALLIED INNOVATIVE SYSTEMS
- Proposal award date
- 2023-06-01
- Contract end date
- 2025-04-30
- UEI
- SFFKG8THUH55
- Solicitation number
- PAS19-316
- Topic code
- NIA
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Highly sensitive immunoassay for determination of biomarkers for neurodegenerative diseases
- A multiplex assay for early detection of Cutaneous T-Cell Lymphoma
- Ultra sensitive method for HIV p antigen detection
- A new hemagglutination method for blood grouping
- A method for the determination of the percentage of CD4 T cells and CD4/CD8 ratio
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers
- A Drug Discovery Platform to Prioritize Development of Natural Product Neuromodulators for Treating Cognitive Impairment
- VR-CARES: Feasibility of Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support to improve social connection, health, and at-home dementia care
- Developing an Integrated Brain State Monitor for Personalized Anesthesia Decision Support: Preventing Postoperative Delirium in Elderly and Patients At Risk for Alzheimer's or Related Dementias
- Lead Optimization of a Therapeutic Candidate for Alzheimer’s Disease
Research funding history
21 SBIR/STTR records share this UEI (2000–2023). Reported award amounts total $10,630,804. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services